The online version of this article (doi:10.1186/1471-230X-14-94) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interest.
GG conceived the clinical case and wrote the manuscript; AD helped to draft the manuscript and designed Figure 1 and Additional file 1: Table S1; UV helped to draft the manuscript and revised the written English; PG, DV, MCS, CD and AP helped to draft the manuscript and revised it critically for important intellectual content; DV and MCS performed the ultra-deep pyro-sequencing of the polymerase region of HBV; all authors read and approved the final manuscript.
Some reports have documented the coexistence of Hepatitis B surfage Antigen (HBsAg) and anti-HBsAg antibodies (HBsAb) in patients with chronic hepatitis B (CHB), often in the absence of amino acid substitutions in the HBsAg sequences of the Hepatitis B Virus (HBV) genome able to explain an immunological escape variant.
HBV genome has a very compact coding organization, with four partially overlapping open reading frames (ORFs). Because the reverse transcriptase region (rt) of HBV polymerase overlaps the HBsAg ORF, it is possible that some mutations in the HBsAg region correspond to mutations in the rt ORF, conferring resistance to current antiviral therapies.
This unique case explores the response to antiviral therapies of a CHB with concurrent HBsAg and HBsAb positivity, and analyse the clinical implications of possible mutations in rt and HBsAg ORFs.
Here we describe the case of a 59 year-old Italian man suffering from Hepatitis B envelope Antigen (HBeAg) positive CHB with concurrent HBsAb positivity. By ultra-deep pyro-sequencing (UDPS) technique, mutations conferring immunological escape or resistance to antiviral therapies were found neither in HBsAg nor in HBV rt ORFs, respectively.
The patient was unsuccessfully treated with interferon, adefovir monotherapy and adefovir plus entecavir combination. Surprisingly, during entecavir plus tenofovir combination, anti-HBe seroconversion and HBsAg loss were observed, while the titer of HBsAb persisted.
Concurrent HBsAg/HBsAb positivity in active CHB is a clinical and virological dilemma. In this setting, there are not consistent data about the response to conventional therapies and the immunological balance between host and virus remains so far unexplained. This is, to our knowledge, the first case described of a CHB with HBsAg/HBsAb positivity, wild type for clinically relevant mutations in HBsAg and rt ORFs, successfully treated with a combination of nucleot(s)ide analogues (NAs).
Tabor E, Gerety RJ, Smallwood LA, Barker LF: Coincident hepatitis B surface antigen and antibodies of different subtypes in human serum. J Immunol Baltim Md 1950. 1977, 118: 369-370.
Torresi J: The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2002, 25: 97-106. CrossRef
Solmone M, Vincenti D, Prosperi MCF, Bruselles A, Ippolito G, Capobianchi MR: Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol. 2009, 83: 1718-1726. 10.1128/JVI.02011-08. CrossRefPubMed
Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL: Adefovir Dipivoxil 437 Study Group: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003, 348: 808-816. 10.1056/NEJMoa020681. CrossRefPubMed
Zhang J-M, Xu Y, Wang X-Y, Yin Y-K, Wu X-H, Weng X-H, Lu M: Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2007, 44: 1161-1169. 10.1086/513200. CrossRef
Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL: Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatol Baltim Md. 1999, 30: 1312-1317. 10.1002/hep.510300511. CrossRef
Frider B, Alessio A, Pozzati M, Cuestas ML, Mathet VL, Oubiña JR: Successful interferon treatment in a patient chronically infected with hepatitis B virus carrying unusual S- (and P-) mutants in the presence of anti-HBs antibodies. Liver Int Off J Int Assoc Study Liver. 2007, 27: 727-730. 10.1111/j.1478-3231.2007.01480.x. CrossRef
Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C: Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology. 2012, 143: 619-628.e1. 10.1053/j.gastro.2012.05.037. CrossRefPubMed
- Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
Antonio De Vincentis
Maria Carmela Solmone
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II